145 related articles for article (PubMed ID: 25031973)
21. Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
Utecht KN; Kolesar J
Am J Health Syst Pharm; 2008 Jul; 65(13):1221-31. PubMed ID: 18574011
[TBL] [Abstract][Full Text] [Related]
22. A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients.
Li F; Yao FS; Zhu XJ; Gu WY; Wang XH; Chen B; Huang DP; Ding JH; Wu TQ; Zhu Y; Zhao Q; Tang YM; Song P; Zhou XG; An ZM; Guo X; Wang XL; Zhong L; Xie XB; Zhai YP
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2343-2355. PubMed ID: 31280348
[TBL] [Abstract][Full Text] [Related]
23. Subcutaneous bortezomib: in multiple myeloma.
Hoy SM
Drugs; 2013 Jan; 73(1):45-54. PubMed ID: 23338539
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Chari A; Rodriguez-Otero P; McCarthy H; Suzuki K; Hungria V; Sureda Balari A; Perrot A; Hulin C; Magen H; Iida S; Maisnar V; Karlin L; Pour L; Parasrampuria DA; Masterson T; Kosh M; Yang S; Delioukina M; Qi M; Carson R; Touzeau C
Br J Haematol; 2021 Mar; 192(5):869-878. PubMed ID: 33216361
[TBL] [Abstract][Full Text] [Related]
25. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.
Lassalle A; Thomaré P; Fronteau C; Mahé B; Jubé C; Blin N; Voldoire M; Dubruille V; Tessoulin B; Touzeau C; Chauvin C; Loirat M; Lok A; Bourcier J; Lestang E; Mocquet R; Barbarot V; Moreau P
Ann Oncol; 2016 Feb; 27(2):314-8. PubMed ID: 26578729
[TBL] [Abstract][Full Text] [Related]
26. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
O'Connor OA
Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
28. Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib?
Gozzetti A; Candi V; Zuanelli Brambilla C; Papini G; Bocchia M
Br J Haematol; 2017 Apr; 177(1):144-147. PubMed ID: 26970245
[No Abstract] [Full Text] [Related]
29. Bortezomib for the treatment of mantle cell lymphoma.
Kane RC; Dagher R; Farrell A; Ko CW; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5291-4. PubMed ID: 17875757
[TBL] [Abstract][Full Text] [Related]
30. New diagnosis of multiple myeloma in a patient with mantle cell lymphoma: Shared genetic factors or simple coincidence?
Sikuyayenga MJ; Reeder CB; Mikhael JR
Leuk Res Rep; 2012; 1(1):7-8. PubMed ID: 24371760
[TBL] [Abstract][Full Text] [Related]
31. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
32. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas.
Paoluzzi L; O'Connor OA
BioDrugs; 2006; 20(1):13-23. PubMed ID: 16573348
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.
McCormack PL
BioDrugs; 2015 Jun; 29(3):207-14. PubMed ID: 26115634
[TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibitors in the treatment of B-cell malignancies.
Schenkein D
Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
[TBL] [Abstract][Full Text] [Related]
35. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Kane RC; Farrell AT; Sridhara R; Pazdur R
Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
[TBL] [Abstract][Full Text] [Related]
36. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
Desplats M; Pascart T; Jelin G; Norberciak L; Philippe P; Houvenagel E; Goeb V; Flipo RM
Clin Rheumatol; 2017 Jun; 36(6):1395-1400. PubMed ID: 28255739
[TBL] [Abstract][Full Text] [Related]
37. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.
Moreau P; Coiteux V; Hulin C; Leleu X; van de Velde H; Acharya M; Harousseau JL
Haematologica; 2008 Dec; 93(12):1908-11. PubMed ID: 18768528
[TBL] [Abstract][Full Text] [Related]
38. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Mujtaba T; Kanwar J; Wan SB; Chan TH; Dou QP
Int J Mol Med; 2012 Jan; 29(1):102-6. PubMed ID: 22012631
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
Genovese MC; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Porawska W; Box J; Legerton C; Nasonov E; Durez P; Aranda R; Pappu R; Delaet I; Teng J; Alten R
Arthritis Rheum; 2011 Oct; 63(10):2854-64. PubMed ID: 21618201
[TBL] [Abstract][Full Text] [Related]
40. Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective.
Carlson J; Cox K; Bedwell K; Ku M
Int J Nurs Pract; 2015 Dec; 21 Suppl 3():1-13. PubMed ID: 26681664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]